← Evidence map

ArticleBritish journal of cancer2021

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).

Francesco Gelsomino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). | OpenQuestion